Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 68-73

  Wu, Duo Jiao ^a   Xu, Jian Zhong ^a   Wu, Yong Jie ^a   Jean Charles, Lafarge ^b   Xiao, Bing ^a   Gao, Ping Jin ^a,c   Zhu, Ding Liang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Sino French Research Center for Life Science and Genomics   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Atherosclerosis; Fasudil; Mice; Micro ultrasound; Plaque

Indexed keywords

APOLIPOPROTEIN E; FASUDIL; LIPID; RHO KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOMICROSCOPY; BLOOD PRESSURE; BRACHIOCEPHALIC TRUNK; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; FLOW RATE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LIPID DIET; LOW DRUG DOSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; BRACHIOCEPHALIC TRUNK; CARDIOVASCULAR AGENTS; CAROTID ARTERY DISEASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMMUNOHISTOCHEMISTRY; LIPIDS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ACOUSTIC; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; TIME FACTORS;

EID: 70350787415     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.025     Document Type: Article

References (14)

1. Shiomi M., and Ito T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 126 4 (1999) 961-968
2. Williams J.K., Sukhova G.K., Herrington D.M., et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 31 3 (1998) 684-691
3. Etienne-Manneville S., and Hall A. Rho GTPases in cell biology. Nature 420 6916 (2002) 629-635
4. Kandabashi T., Shimokawa H., Mukai Y., et al. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22 2 (2002) 243-248
5. Mallat Z., Gojova A., Sauzeau V., et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93 9 (2003) 884-888
6. Rawlings R., Nohria A., Liu P.Y., et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 103 4 (2009) 437-441
7. Gan L.M., Grönros J., Hägg U., et al. Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. Atherosclerosis 190 2 (2007) 313-320
8. Wendelhag I., Gustavsson T., Suurkula M., et al. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. Clin Physiol 11 6 (1991) 565-577
9. Johnson J., Carson K., Williams H., et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 111 11 (2005) 1422-1430
10. Staikov I.N., Arnold M., Mattle H.P., et al. Comparison of the ECST, CC, and NASCET grading methods and ultrasound for assessing carotid stenosis. European Carotid Surgery Trial. North American Symptomatic Carotid Endarterectomy Trial. J Neurol. 247 9 (2000) 681-686
11. Wang Y.X., Martin-McNulty B., da Cunha V., et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111 17 (2005) 2219-2226
12. Kanda T., Hayashi K., Wakino S., et al. Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 45 4 (2005) 724-729
13. Mukai Y., Shimokawa H., Matoba T., et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 15 6 (2001) 1062-1064
14. Higashi M., Shimokawa H., Hattori T., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93 8 (2003) 767-775